Why Is Unicycive Therapeutics Stock (UNCY) Down 35% Today?
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Due to these deficiencies, the FDA has precluded any label discussions surrounding a New Drug Application for oxylanthanum carbonate. This is the company's treatment for hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive Therapeutics expects a final decision from the FDA by June 28, 2025.
UNCY stock dropped 35.56% alongside today's news and is down 31.65% year-to-date. Despite this, the shares are still up 37.4% over the past 12 months.
Is Unicycive Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Unicycive Therapeutics is Strong Buy, based on six Buy ratings over the last three months. With that comes an average UNCY stock price target of $6.67, representing a potential 1,012.04% upside for the shares.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
DOJ reaches $9.8 million settlement with Illumina over cyber whistleblower claims
This story was originally published on Cybersecurity Dive. To receive daily news and insights, subscribe to our free daily Cybersecurity Dive newsletter. The Department of Justice on Thursday announced a $9.8 million settlement with Illumina over allegations that the company sold genomic-sequencing systems with software vulnerabilities to federal agencies for multiple years. Between 2016 and 2023, the government said, the company sold the systems without having an adequate security program and knowingly failed to incorporate cybersecurity into its product design process. According to prosecutors' complaint, Illumina is the dominant company in the global market, with a share of roughly 80%. 'Companies that sell products to the federal government will be held accountable for failing to adhere to cybersecurity standards and protecting against cybersecurity risks,' Assistant Attorney General Brett Shumate of the DOJ's Civil Division said in a statement. 'This settlement underscores the importance of cybersecurity in handling genetic information and the department's commitment to ensuring that federal contractors adhere to requirements to protect sensitive information from cyber threats,' he added. Illumina denied the allegations that it knowingly sold defective products, and the agreement states that the company is not making any admissions related to those claims. The Food and Drug Administration in 2023 issued a warning about a vulnerability in Illumina software that could allow an attacker to change settings on the device or even take it over remotely. In 2022, the Cybersecurity and Infrastructure Security Agency warned about a flaw in Illumina's Local Run Manager software that could allow an attacker to remotely alter test results. The company later patched the flaw. The case involved a whistleblower — Erica Lenore, a former director of platform management at Illumina — who provided the government with details about the company's alleged noncompliance. Lenore will receive $1.9 million from the settlement. Illumina said while it disagrees with the allegations from the government, it decided to settle the matter due to the 'uncertainty, expense and distraction' of litigating the case. The company noted the claims related to software issues, which Illumina says it successfully remediated from 2022 to 2024. 'Government agencies, including the U.S. Food and Drug Administration (FDA), are important customers and Illumina values these relationships,' the company said in a statement. 'Illumina takes data security seriously and has invested significantly in its programs to align with cybersecurity best practices for the development and deployment of our products. DOJ also reached a $1.75 million settlement with defense contractor Aero Turbine Inc. and private equity firm Galant Capital Partners, over claims they failed to meet cybersecurity standards related to an Air Force contract. The DOJ did credit them for voluntarily coming forward to cooperate in the case. (Updates with comments from company) Recommended Reading US government plays catchup on phishing-resistant MFA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the penny stocks that will skyrocket. On July 25, the company confirmed it is eyeing $80 million in gross proceeds on the execution of a securities purchase agreement as part of a registered direct offering. It also plans to issue common stock and warrants for the purchase of additional shares. M. A. Arkhipov/ Once fully exercised, the warrants could yield up to $96 million in gross proceeds. Piper Sandler and Co. is acting as the placement agent of the registered direct offering. The net proceeds from the offering are expected to provide the company with much-needed working capital and support for its ongoing business operations. The direct offering comes on the company's ANKTIVA product, receiving FDA approval as an immunotherapy for non-muscle invasive bladder cancer. The flagship product is designated for FDA Breakthrough Therapy. ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing next-generation immunotherapies and vaccines that harness the power of the immune system to fight cancer and infectious diseases. It seeks to create durable and safe protection against diseases by developing innovative therapies and cell therapies that bolster the natural immune response. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is . On July 11, BofA Securities initiated coverage of the stock with a 'Buy' rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company's Taysha gene therapy TSHA-102 under development for Rett Syndrome. Copyright: dolgachov / 123RF Stock Photo The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones. Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity. Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotech company focused on developing and bringing to market gene therapies for serious monogenic disorders affecting the central nervous system. It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies. While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
